Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium, quantity: 91.363 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; maize starch; microcrystalline cellulose; magnesium stearate - for the treatment of osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; iron oxide yellow; macrogol 400; hypromellose; titanium dioxide; iron oxide red; microcrystalline cellulose - treatment of osteoporosis. treatment of glucocorticoid induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy

Австралия - английски - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; colloidal anhydrous silica; magnesium stearate; propylene glycol; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; croscarmellose sodium - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression, in adults, of chronic, recurrent urinary tract infection.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azithromycin dihydrate, quantity: 524.05 mg (equivalent: azithromycin, qty 500 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; hyprolose; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - apo-azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity:,1. lower respiratory tract infections:,? acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis. ? community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. ? community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.,2. upper respiratory tract infections:,? acute sinusitis due to streptococcus pneumoniae or haemophilus influenzae. ? acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.,3. uncomplicated skin and skin structure infections:,? uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage.,4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis.,? note: at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. ? apo-azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivitis and trachoma.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note. specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infection.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 23.705 mg (equivalent: vardenafil, qty 20 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 11.852 mg (equivalent: vardenafil, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 5.926 mg (equivalent: vardenafil, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 628.93 mg (equivalent: azithromycin, qty 600 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; calcium phosphate; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis. community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemphilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. note. at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivits and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy. azithromycin is indicated for use in children for the treatment of the following infections: 1. acute streptococcal pharyngitis/tonsillitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20mg/kg azithromycin dose appears to be almost as effective as penicillin in the treatment of streptococcal pharyngitis. however substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections: acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenzae or moraxella catarrhalis. community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment. community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae. 2. upper respiratory tract infections: acute sinusitis due to streptococcus pneumoniae or haemphilus influenzae. acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. uncomplicated skin and skin structure infections: uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage. 4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis. note. at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required. azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivits and trachoma. azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/microliter (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy. azithromycin is indicated for use in children for the treatment of the following infections: 1. acute streptococcal pharyngitis/tonsillitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20mg/kg azithromycin dose appears to be almost as effective as penicillin in the treatment of streptococcal pharyngitis. however substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.